Screening for breast cancer can result in early detection of malignancies and lives saved. Many employers now offer periodic screening as an employee health benefit, and some have established screening programs in the workplace. This study was performed to identify the employer costs of breast cancer screening in the workplace, referrals for suspicious findings, and initial treatment of malignant disease. Additionally, the costs for these same services, had they been obtained outside of a workplace screening program, were estimated.
Data on program components and associated costs for an established employer based breast cancer screening program were obtained. These costs were compared to those among a hypothetical cohort of women not enrolled in the workplace screening program.
From 1989 through 1995, 1,416 women participated in the program. Nearly 2,500 screening mammograms and approximately 2,773 clinical breast examinations were performed, resulting in 292 referrals to physicians outside of the program for additional diagnostic procedures and treatment as needed. These referrals resulted in the detection of 12 malignancies: 8 Stage I; 3 Stage II; and 1 Stage III. Mammographic and clinical breast examination screening cost $249,041; referrals resulting in benign disease or no detectable disease cost $185,002; and referrals resulting in malignant disease, followed by initial treatment, cost $148,530. Therefore, the total cost was $582,573. Approximately 47% of the cost of referrals and initial treatment were due to employee lost productivity. Total cost in the hypothetical cohort was $1,067,948 under the assumptions that all women received screening outside of the workplace, and that the same number of malignancies were detected at the same stage as in the workplace program.
These findings indicate referrals resulting in detection of benign disease or no disease accounted for a substantial proportion of the total cost of the program. In addition, employee lost productivity accounted for almost 50% of the cost of all referrals and initial treatment. Workplace screening is a relatively efficient approach for early detection of breast cancer when compared to off site screening or no screening. The efficiency could be improved with a reduction in the number and cost of unnecessary referrals. B reast cancer is now widely recognized as an important cause of morbidity and mortality among working aged women, with important economic consequences for both employees and employers (Kelsey, 1991) . Therefore, many employers now offer insurance coverage for periodic screening related to breast cancer through the employee's routine source of care. Alternatively, employers may offer screening at the workplace (Greenwood, 1996; Griffiths, 1996; Kessler, 1991) . Some contract with a mobile mammography unit brought periodically to the worksite. Others own and operate mammography equipment and also offer clinical breast examination at the workplace.
Programs in which employers own their equipment and provide screening on site are relatively new. Thus, little is known about their costs to employers and employees. In addition, because screening services and populations screened may vary, little is known about the rate and cost of referrals for suspicious findings through screening, or about the rate at which malignancies are detected. Continued diffusion of such programs may depend on evaluation of their costs relative to other types of programs, such as those offered through the employee's routine source of care. Also, it may depend on the rate of malignancies detected through screening relative to the total number and cost of referrals that result in the detection of benign breast disease or no disease.
This study was performed to identify the employer costs of a workplace breast cancer screening program, and to determine the economic impact of referrals resulting in the detection of malignancies, benign disease, or no disease.
METHODOLOGY

Design
A retrospective cohort study of women enrolled in a workplace breast cancer screening program was performed to identify the costs, from the perspective of the employer, for breast cancer screening, referrals based on suspicious findings due to screening, and initial treatment of malignancies identified through screening. Also, these costs were compared to the estimated costs of screening, referral, and treatment among a hypothetical cohort of women without access to a workplace screening program.
524
Sample
Zeneca Pharmaceuticals, Inc. (Zeneca) employs approximately 1,200 women at its United States headquarters in Wilmington, DE. Through its Health Services Medical Department, Zeneca offers screening programs for breast, prostate, and colorectal cancers, as well as general wellness and fitness programs.
The breast cancer screening program was begun in January 1989 to increase awareness of, and participation in, early detection of breast cancer, with the goal of increasing the chances of cure and decreasing mortality associated with this disease. All female employees of Zeneca are eligible to participate in the program, offered on site during regular work hours. The program is accredited by the American College of Radiology and the Food and Drug Administration. It consists of screening mammography, clinical breast examination, and instruction about breast self examination. In 1989, Zeneca purchased a mammography machine and made necessary alterations to its property to operate the machine. The company contracts with a radiologic technician who performs the mammographies, and a radiology company for film processing and interpretation. The results are reported back to the Health Services Medical Department, which informs the employee of the results.
Baseline mammography is provided to women age 35 to 38 years upon the request of a physician; biennial mammography is provided from age 40 to 50; and annual mammography is provided after the age of 50. Clinical breast examination (CBE) follows the American Cancer Society Guidelines on Screening for Breast Cancer, with examination at the time of the baseline mammogram and annual examination after age 40 (Dodd, 1992) . CBE is usually performed when mammography is performed. Additionally, it may be performed any time the employee requests. All examinations are performed by a trained registered nurse/certified occupational health nurse. Breast self exam instruction is offered through both classes and videotape. In addition, other educational and psychosocial components are incorporated into the program. Current facts about breast cancer are communicated to all employees enrolled in the program through newsletters and bulletins, and counseling is offered when there is a suspicious finding.
When a suspicious finding occurs on either a mammogram or CBE, the Health Services Medical Department provides assistance to the employee in obtaining follow up care. The employee may elect to consult the on site physician to determine whether diagnostic evaluation is needed. Alternatively, the employee may elect to consult a family physician, radiologist, or surgeon. Once the employee has decided where to obtain care, a report of the screening results are provided to that physician.
Data Collection
Using records maintained for program administration, the researchers identified all women enrolled in the program anytime from January 1989 through December 1995. From these records the following data were obtained:
• Annual data about the number of mammograms and CBEs performed. • The number of referrals due to suspicious findings on a mammogram, CBE, or both. • The number of malignancies, by stage.
The number of CBEs performed without mammography during 1989 and 1992 were not available. To estimate this number, the total number of CBEs was divided by the total number of mammograms performed from 1993 through 1995. The quotient was then multiplied by the total number of mammograms performed from 1989 through 1992. For referrals in 1992 through 1995, the researchers identified medical and surgical visits, additional diagnostic procedures, and resources for initial management of malignancies. Data on specific medical resources were not available for all of the referrals from 1989 through 1991. Therefore, it was assumed that the medical resources used during these referrals were similar to those used for referrals with available resource data.
Other data included capital, labor, supply, and administrative inputs for screening. Capital inputs consist of the mammography machine, space for the machine, CBE, counseling and program administration, maintenance of the machine, and certification. The cost of the mammography machine when purchased in 1989, and the cost of modifications to the space housing the machine necessary for certification were calculated. It was assumed these capital expenses were being depreciated (straight line) over 15 years. The mammography machine, housed in a 100 square foot room, was used approximately 50% of the time for mammography. CBE and counseling were provided in another 100 square foot room, used approximately 17% of the time. To obtain the total cost of space used, the cost per square foot of space was multiplied by the total square feet of space for the program. This product was weighted by the percentage of time the space was used for program purposes. The annual costs of maintaining and certifying the mammography machine were obtained.
Labor inputs included a certified occupational health nurse, radiologic technician, radiologist, and Health Services Medical Department physician time. Based on interviews with program staff, it was estimated a certified occupational health nurse spent approximately 40 minutes per encounter including both mammography and CBE. Included in this calculation was time spent performing additional CBEs and administrative tasks related to the program. A cost was assigned to this component of labor based on the average annual salary for a certified occupational health nurse among members of the Delaware Association of Occupational Health Nurses. It was estimated a trained radiologic technician can perform four mammograms per hour, at an hourly wage rate based on prevailing rates in the area. Approximately 5% of women are seen by the Health Services Medical Department physician because they have questions or concerns about screening or they have a suspicious finding. The physician spent 10 minutes with each woman. Finally, an assumption was made each woman misses .5 hours of work per encounter including both mammography and CBE, factoring in NOVEMBER 1998, VOL. 46, NO. 11 abbreviated lost time for CBE alone. The estimated hourly wage of women in the program was used to compute the lost productivity cost of screening.
Supplies consisted of radiographic film and radiology capes. Administrative inputs included computer time and software, phone, and mailings. The researchers obtained labor, supply, and administrative cost data for 1993. These costs were inflated to 1996 dollars. Labor costs were inflated at 5% per year; supply and administrative costs were inflated at 8.5% per year. Equipment maintenance and certification costs were also inflated from 1993 to 1996 dollars at 8.5%. However, depreciation and space costs were not inflated. The labor, supply, and administrative costs per screen were calculated. To obtain the total cost of the screening program, the number of encounters including both mammography and CBE were multiplied by the variable labor, supply, administrative, and lost productivity costs per encounter. This figure was added to the fixed cost of 7 years of depreciation on the mammography machine, of space utilization, of certification, and of equipment maintenance. The total cost was divided by the total number of encounters to obtain the average cost per encounter.
To calculate the medical cost of referrals and initial treatment of malignancies, resource specific usual, customary, and reasonable charges paid out by the company's Health Claims Service were obtained. Both facility and professional charges were used. In addition to the direct medical costs of care, it was estimated the average referral resulted in 2 days of missed work at $17 per hour. Because referral data for 1989 through 1991 were incomplete, an average cost per referral for participants in 1992 through 1995 ($382) was computed and applied to all 1989 referrals (n = 43), 17 referrals in 1990 missing cost data, and 20 referrals in 1991 missing cost data. Finally, it was estimated treatment of, and morbidity due to Stage I, Stage II, or Stage III cancer resulted in an average of 4.5 weeks of medical leave of absence. The individuals were paid at the full pay rate ($17 per hour) for the first 8 weeks and then $579 per month thereafter (Griffiths, 1994) . None of these malignancies resulted in permanent disability or death.
Analysis
The total direct health care and lost productivity costs of screening, referrals, and initial management of malignancies were added to determine the total cost of the program. This cost was compared to the estimated costs of screening, referral, and initial treatment of breast cancer among an identically sized cohort of women not enrolled in the program. This cohort assumed the same number of screenings and subsequent follow up visits as in the workplace program population, and malignancies were detected at the same stage as in the workplace program.
The cost of a mammogram outside the program was obtained from the usual, customary, and reasonable charges reimbursed by the company's Health Claims Service. Documentation of lost productivity associated with these mammograms was obtained from the literature (Griffiths, 1994) . The cancer stage specific costs of referral and treatment calculated in the workplace population 
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were assigned to this hypothetical population. Lastly, it was assumed the costs of referrals and initial management of Stage IV cancers were the same as those of the Stage ill malignancies.
RESULTS
From 1989 through 1995, 1,416 women participated in the breast cancer program; During this period, 2,498 screening mammograms and 2,773 CBEs were performed. The total cost of screening mammography and CBB was $249,041 (see Table 1 ). The average cost per screen was $100. Capital equipment accounted for 20%, labor accounted for 23%, supplies accounted for 48%, administration accounted for less than 1%, and lost productivity accounted for 9% of the total cost. Suspicious findings resulted in 292 referrals. Of the 292 women, 148 were referred to a general internist, 62 were referred to a surgeon, and 8 visited both a general internist and a surgeon. Ninety-six of these women hadan additional mammography as part of their follow up care. Detailed components of follow up care were not available for 74 cases. However, all of these cases resulted in a diagnosis of benign breast disease or no disease. 1\velve referrals (4% of all referrals) resulted in the detection of a malignancy, while the remaining 280 referrals resulted in the identification of benign breast disease or no disease. Eight of the malignancies (67%) were diagnosed at Stage I, 3(25%) were diagnosed at Stage II, and 1 (8%) was diagnosed at Stage ill.
Medical resources and associated costs for referrals that resulted in the detection of benign or no disease, and for referrals and initial treatment of malignant disease, are shown in Table 2 . The total cost of referrals and initial management of malignant disease was $333,532. Referrals resulting in detection of benign disease or no disease.cost $185,002. Detection and initial treatment of malignant disease referrals cost $148,530. Approximately 41% of the referral costs resulting in detection of benign disease or no disease and 54% of the referral costs resulting in the detection and initial treatment of malignant disease were due to employee lost productivity (lost employee work time).
The average cost of diagnosis and treatment per malignancy was $10,998 for Stage I, $14,289 for Stage II, and $17,683 for Stage ill (one case only) disease. For malignancies , 54% of the cost was due to short term lost productivity plus long term disability, while 20% was due to mastectomy.
The costs of screening, referrals, and treatment of malignancies for the hypothetical cohort of women are shown in Table 3 . Screening costs included fees of $225 and $69 for an offsite mammogram and associated lost productivity per mammogram, respectively. As shown, the costs in the hypothetical cohort are greater than the costs of the workplace program . Additionally, only 14% of program costs in the cohort are due to the diagnosis and treatment of malignant disease.
DISCUSSION
This study was performed to identify the costs of screening, referral, and initial management of malignan- cies associated with a breast cancer screening program implemented in the workplace. In addition, the study compared these costs to the estimated costs of screening and treatment, had the program not been available to the cohort of participating employees. The findings are noteworthy for several reasons. First, although the majority of costs were due to screening mammography and CBEs, 32% of the total cost was for referrals that resulted in the detection of benign breast disease or ruling out disease. For each referral resulting in detection of a malignancy (n =12), 23 resulted in the detection of benign disease or no dis- NOVEMBER 1998, VOL. 46, NO. 11 ease (n =280). This indicates the false positive rate for screening mammography and/or CBE had an important impact on the overall program cost. Reduction in the referral rate of false positives and the cost of a referral could result in a significant reduction in the cost of the screening program. The number of false positives is a function of both the underlying prevalence of malignancy in the population screened and the sensitivity and specificity of the screening test. Therefore, limiting screening to a population in which the incidence of disease is believed to be higher, e.g., an older population, could reduce the number of false positive referrals. How- It has been previously demonstrated the specificity of screening is a much more important determinant of cost than the underlying incidence of disease. Therefore, it is likely that adopting more specific referral criteria, e.g., screening mammogram following a suspicious CBE. results in a lower false positive rate than attempting to select a population at higher risk. Criteria for screening has been subject to debate. Current mammography screening guidelines presented by the National Cancer Institute (1997) recommend women in their 40s or older be screened on a regular basis, every 1 to 2 years. Additionally, women at increased risk for breast cancer should seek health care advice about when to begin mammograms and screening frequency.
The American Cancer Society (1997) recommends all women begin mammography screening by age 40 and continue screening every 1 to 2 years. Upon reaching age 50, women should undergo mammography screening every year. However, it should be noted that adopting . more stringent criteria for referral could result in missing most of the minimal or early stage cancers. More efficient utilization of health care resources during referral , such as minimally invasive biopsies instead of open biopsies, where appropriate, also could reduce direct health care costs.
Second, lost productivity accounted for approximately 41% of the referral costs for benign or no disease, and approximately 54% of the cost of referrals and initial treatment for malignant disease . In addition, more than 18% of the difference in cost between the workplace screening program and the hypothetical cohort of women who obtained screening outside of the workplace was due to assumed differences in the cost of lost productivity due to screening. These findings suggest lost productivity costs comprise a significant component of total costs from the perspective of the employer and, potentially, the employee. Failure to account for these costs when decid-528 ing how to develop an efficient screening program could result in significantly underestimating the cost of a program based in the workplace. However, this could also result in overestimating the cost of this program relative to one offering similar screening services offsite in which the lost productivity costs associated with screening are likely to be even greater.
This study has several limitations. First, while data on resource utilization for initial treatment of malignancies, including mastectomy, breast reconstruction, and radiation therapy, were available, data on the costs of subsequent care could not be obtained. Therefore, the costs of all periodic follow up care may not have been included. This omission could have resulted in underestimating total cost. However, it has no impact on the estimates of the cost of screening. All the women diagnosed with a malignancy are alive, indicating there have been no costs for terminal care.
Second, although data on women who participated in the worksite screening program were obtained, data on a comparable cohort of women who did not participate, for purposes of comparing cost, were not available. Instead, it was necessary to construct the hypothetical cohort and make assumptions both about the care seeking behavior of women not enrolled in the program and about the stage of cancer at detection. Also, it was assumed that the same number of malignancies observed in the workplace program was detected in the hypothetical cohort. This does not account for the possibility that slow growing, early stage cancers detected in the screened population would not have been detected in the unscreened population during the period of observation. If this were the case, the cost of cancer care in the hypothetical cohort would be lower than estimated.
Third, the study was conducted at a single company. Because this workplace screening program was comprised of a relatively small number of enrollees and subsequent screenings and follow up examinations, calculated costs and benefits of this screening program may not be a reliable and valid indicator of costs and benefits at other screening programs. Other companies with worksite breast cancer screening programs might incur larger or smaller costs and savings, depending on the nature of their health insurance and disability benefits packages . For instance, employers with less generous disability benefits might incur significantly lower costs for malignancies detected at later stages.
Nonetheless, while actual costs and benefits may fluctuate among programs, it is believed that the major cost components and health benefits of breast cancer screening programs as a whole have been illustrated. Also, at this company baseline screening was offered to all women age 38 or older or to younger women on the advice of their primary care provider, with biennial screening to age 49 and annual screening 'from age 50 through retirement. As shown, a significant percentage of program costs resulted from referrals for benign breast disease or no disease. The referral rate for women without malignancies could be higher or lower in other set-. tings depending on the content and quality of screening
What Does This Mean in the Workplace?
Workplace breast cancer screening programs are a relatively efficient approach for the early detection of breast cancer when compared to offsite screening or no screening. However, employers need to be aware that the indirect costs of lost productivity due to referrals based on suspicious screening findings can be a major cost component, as can referrals resulting in the detection of benign disease or no disease. Employers interested in implementing such a program need to take these costs into consideration. and on the age and sociodemographic characteristics of the women screened. This could result in higher or lower absolute or relative costs of screening in the workplace. Fourth, the.impact of workplace screening on mortality or morbidity was not explored. Though lost productivity during screening, diagnosis, and initial treatment was accounted for, the researchers did not compute the years of productive life saved due to breast cancer screening. Finally, although BSE instruction was noted as a component of the breast cancer screening program, costs associated with this component were not included in the cost estimates. In addition, no data were available about abnormalities detected by program participants through BSE.
The findings indicate referrals resulting in the detection of benign disease or no disease accounted for a significant proportion of the total cost of the program. In addition, employee lost productivity accounted for almost 50% of the cost of all referrals and initial treatment. Although the study was limited somewhat by lack of a high volume, low cost setting with high quality NOVEMBER 1998, VOL.46, NO. 11 mammography for use as a comparison scenario, the approach taken in this workplace screening program appears to be relatively efficient. Employers and employees should realize that efficiency within a screening program is determined by many factors including the population within the program, the age at which screening services are provided, and the quality of screening technique used.
CONCLUSION
Workplace breast cancer screening programs are a relatively efficient approach for the early detection of breast cancer when compared to off site screening. However, the indirect costs of lost productivity due to referrals based on suspicious screening findings can be a major cost component, as can referrals resulting in the detection of benign disease or no disease. These costs need to be weighed by health care professionals interested in implementing such a program.
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